Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:EIGR
- CUSIP: N/A
- Web: www.eigerbio.com
Capitalization:- Market Cap: $65.68 million
- Outstanding Shares: 8,367,000
Average Prices:- 50 Day Moving Avg: $8.43
- 200 Day Moving Avg: $8.94
- 52 Week Range: $6.10 - $16.82
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.52
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.47 per share
- Price / Book: 3.18
Profitability:- EBIDTA: ($46,280,000.00)
- Return on Equity: -128.94%
- Return on Assets: -88.88%
Debt:- Debt-to-Equity Ratio: 0.72%
- Current Ratio: 7.01%
- Quick Ratio: 7.01%
Misc:- Average Volume: 79,141 shs.
- Beta: 2.51
- Short Ratio: 0.88
Frequently Asked Questions for Eiger BioPharmaceuticals (NASDAQ:EIGR)
What is Eiger BioPharmaceuticals' stock symbol?
Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger BioPharmaceuticals' earnings last quarter?
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Monday, August, 14th. The company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.28) by $0.05. View Eiger BioPharmaceuticals' Earnings History.
When will Eiger BioPharmaceuticals make its next earnings announcement?
Where is Eiger BioPharmaceuticals' stock going? Where will Eiger BioPharmaceuticals' stock price be in 2017?
4 brokers have issued 1 year price objectives for Eiger BioPharmaceuticals' stock. Their predictions range from $27.00 to $36.00. On average, they expect Eiger BioPharmaceuticals' stock price to reach $32.60 in the next twelve months. View Analyst Ratings for Eiger BioPharmaceuticals.
What are analysts saying about Eiger BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Eiger BioPharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (8/16/2017)
- 2. Wedbush analysts commented, "The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors." (6/21/2017)
Who are some of Eiger BioPharmaceuticals' key competitors?
Some companies that are related to Eiger BioPharmaceuticals include Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), Pluristem Therapeutics (PSTI), Genocea Biosciences (GNCA), Tissue Regenix Group PLC (TRX), Oramed Pharmaceuticals (ORMP), Silence Therapeutics plc (SLN), CytRx Corporation (CYTR), GTx (GTXI), Vernalis plc (VER), Regulus Therapeutics (RGLS), Zynerba Pharmaceuticals (ZYNE), Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB) and Galectin Therapeutics (GALT).
Who are Eiger BioPharmaceuticals' key executives?
Eiger BioPharmaceuticals' management team includes the folowing people:
- David A Cory, President, Chief Executive Officer, Director
- James H. Welch, Chief Financial Officer
- Rebecque J. Laba, Vice President - Corporate Operations
- Jeffrey J. Rudy, Vice President - Clinical Operations
- Ryan K. Takeya, Vice President - Manufacturing
- James P. Shaffer, Chief Business Officer
- David Apelian M.D. Ph.D., Director
- Charles Bramlage, Director
- Thomas J. Dietz, Director
- Edgar G. Engleman M.D., Director
Who owns Eiger BioPharmaceuticals stock?
Eiger BioPharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (21.36%), InterWest Venture Management Co (19.12%), Sphera Funds Management LTD. (4.61%), Vanguard Group Inc. (1.20%), Hikari Power Ltd (0.73%) and DAFNA Capital Management LLC (0.43%). Company insiders that own Eiger BioPharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger BioPharmaceuticals.
Who sold Eiger BioPharmaceuticals stock? Who is selling Eiger BioPharmaceuticals stock?
Who bought Eiger BioPharmaceuticals stock? Who is buying Eiger BioPharmaceuticals stock?
Eiger BioPharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Goldman Sachs Group Inc., LMR Partners LLP, Susquehanna International Group LLP and Bank of New York Mellon Corp. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger BioPharmaceuticals.
How do I buy Eiger BioPharmaceuticals stock?
Shares of Eiger BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger BioPharmaceuticals' stock price today?
One share of Eiger BioPharmaceuticals stock can currently be purchased for approximately $7.85.
MarketBeat Community Rating for Eiger BioPharmaceuticals (NASDAQ EIGR)MarketBeat's community ratings are surveys of what our community members think about Eiger BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Eiger BioPharmaceuticals (NASDAQ:EIGR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $32.60 (315.29% upside) |
Analysts' Ratings History for Eiger BioPharmaceuticals (NASDAQ:EIGR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/15/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $36.00 | Low |  |
| 8/14/2017 | Wedbush | Reiterated Rating | Ourperform | $34.00 | Low | |
| 7/14/2017 | BTIG Research | Initiated Coverage | Buy | $32.00 | High | |
| 6/8/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $34.00 | Low | |
| 5/15/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $28.00 -> $27.00 | Medium | |
(Data available from 8/21/2015 forward)
Earnings History for Eiger BioPharmaceuticals (NASDAQ:EIGR)Earnings History by Quarter for Eiger BioPharmaceuticals (NASDAQ EIGR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($1.28) | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($1.28) | ($1.33) | | | View | N/A | |
| 5/12/2017 | Q1 2017 | ($1.35) | ($1.34) | | | View | N/A | |
| 3/23/2017 | Q4 2016 | ($1.38) | ($1.53) | | | View | N/A | |
| 11/8/2016 | Q3 2016 | ($1.21) | ($1.49) | | | View | N/A | |
| 8/10/2016 | Q2 | ($1.17) | ($1.87) | | | View | N/A | |
| 5/16/2016 | Q1 | ($1.69) | ($10.42) | | | View | N/A | |
| 8/11/2015 | Q2 | ($0.32) | ($0.69) | | | View | N/A | |
| 3/31/2015 | Q414 | ($0.36) | ($0.49) | | | View | N/A | |
| 11/12/2014 | Q3 2014 | ($0.39) | ($0.40) | | | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.39) | ($0.38) | | | View | N/A | |
| 5/13/2014 | Q1 2014 | ($0.44) | ($0.58) | | | View | N/A | |
| 3/31/2014 | Q4 2013 | ($0.47) | ($7.96) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)2017 EPS Consensus Estimate: ($4.93)
2018 EPS Consensus Estimate: ($4.56)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($1.37) | ($1.10) | ($1.24) |
| Q2 2017 | 3 | ($1.51) | ($0.93) | ($1.21) |
| Q3 2017 | 3 | ($1.33) | ($1.04) | ($1.22) |
| Q4 2017 | 3 | ($1.48) | ($1.07) | ($1.27) |
| Q1 2018 | 1 | ($1.14) | ($1.14) | ($1.14) |
| Q2 2018 | 1 | ($1.14) | ($1.14) | ($1.14) |
| Q3 2018 | 1 | ($1.14) | ($1.14) | ($1.14) |
| Q4 2018 | 1 | ($1.14) | ($1.14) | ($1.14) |
(Data provided by Zacks Investment Research)
Dividend History for Eiger BioPharmaceuticals (NASDAQ:EIGR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Eiger BioPharmaceuticals (NASDAQ:EIGR)Insider Ownership Percentage: 28.80%
Institutional Ownership Percentage: 69.04%
Insider Trades by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/18/2016 | Jeffrey S Glenn | Director | Buy | 15,460 | $12.74 | $196,960.40 | |
| 8/18/2016 | James P Shaffer | Insider | Buy | 3,125 | $15.70 | $49,062.50 | |
| 8/18/2016 | Ventures Fund Vi L.P. Vivo | Major Shareholder | Buy | 187,500 | $16.00 | $3,000,000.00 | |
| 6/22/2016 | James H Welch | CFO | Buy | 2,500 | $19.80 | $49,500.00 | |
| 6/13/2016 | James P Shaffer | Insider | Buy | 1,250 | $22.17 | $27,712.50 | |
| 5/23/2016 | James P Shaffer | Insider | Buy | 1,245 | $19.80 | $24,651.00 | |
| 4/6/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $18.20 | $872,344.20 | |
| 4/2/2015 | Rebecque J Laba | VP | Sell | 11,012 | $17.30 | $190,507.60 | |
| 3/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $24.80 | $1,188,688.80 | |
| 3/6/2015 | Peter Honig | Director | Sell | 9,700 | $23.74 | $230,278.00 | |
| 3/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $23.06 | $322,840.00 | |
| 3/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $18.48 | $143,718.96 | |
| 2/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $15.86 | $760,185.66 | |
| 2/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $16.08 | $225,120.00 | |
| 2/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $16.35 | $127,153.95 | |
| 1/9/2015 | Jeffrey J Rudy | VP | Sell | 10,000 | $18.51 | $185,100.00 | |
| 1/7/2015 | Rebecque J Laba | VP | Sell | 20,000 | $17.30 | $346,000.00 | |
| 1/6/2015 | Krisztina M Zsebo | CEO | Sell | 41,302 | $17.51 | $723,198.02 | |
| 1/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $19.88 | $154,606.76 | |
| 12/9/2014 | Jeffrey J Rudy | VP | Sell | 10,000 | $15.00 | $150,000.00 | |
| 12/9/2014 | Krisztina M Zsebo | CEO | Sell | 41,302 | $15.00 | $619,530.00 | |
| 12/5/2014 | Rebecque J Laba | VP | Sell | 20,000 | $12.77 | $255,400.00 | |
| 12/1/2014 | Ryan K Takeya | VP | Sell | 7,777 | $12.01 | $93,401.77 | |
| 2/4/2014 | Enterprise Partners Management | Major Shareholder | Buy | 133,083 | $8.00 | $1,064,664.00 | |
| 2/4/2014 | Fredrik Wiklund | VP | Buy | 20,000 | $8.00 | $160,000.00 | |
| 2/4/2014 | Todd Foley | Director | Buy | 111,608 | $8.00 | $892,864.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Eiger BioPharmaceuticals (NASDAQ:EIGR)
Latest Headlines for Eiger BioPharmaceuticals (NASDAQ:EIGR)
| Source: |
|
| Date | Headline |
|---|
 | Q3 2017 EPS Estimates for Eiger BioPharmaceuticals, Inc. Reduced by Oppenheimer Holdings (EIGR)
www.americanbankingnews.com - August 18 at 6:42 AM |
 | Eiger BioPharmaceuticals (EIGR) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 18 at 12:31 AM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 16 at 5:40 PM |
| Eiger BioPharmaceuticals, Inc. Forecasted to Post Q3 2017 Earnings of ($1.29) Per Share (EIGR)
www.americanbankingnews.com - August 16 at 6:46 AM |
| Research Analysts Issue Forecasts for Eiger BioPharmaceuticals, Inc.'s Q3 2017 Earnings (EIGR)
www.americanbankingnews.com - August 16 at 6:46 AM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Announces Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 15 at 12:46 PM |
 | Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 6:35 PM |
| Eiger BioPharma reports 2Q loss
finance.yahoo.com - August 14 at 6:35 PM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Rating Reiterated by Wedbush
www.americanbankingnews.com - August 14 at 11:40 AM |
| Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th
finance.yahoo.com - August 8 at 5:56 PM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 8 at 8:50 AM |
 | Eiger BioPharmaceuticals (EIGR) Receives FDA Fast Track ... - StreetInsider.com
www.streetinsider.com - July 27 at 6:44 PM |
| Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
finance.yahoo.com - July 27 at 6:44 PM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 26 at 6:17 PM |
| Eiger BioPharmaceuticals (EIGR) Reports Complete Enrollment in ... - StreetInsider.com
www.streetinsider.com - July 24 at 10:07 AM |
| Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
finance.yahoo.com - July 24 at 10:07 AM |
| Eiger BioPharmaceuticals, Inc. (EIGR) Expected to Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - July 20 at 8:20 PM |
 | Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24% - Nasdaq
www.nasdaq.com - July 17 at 7:09 PM |
| Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24%
finance.yahoo.com - July 17 at 11:09 AM |
| BTIG Research Begins Coverage on Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
www.americanbankingnews.com - July 15 at 10:52 PM |
| Mid-Day Market Update: A10 Networks Drops Following Guidance Cut; Celadon Group Shares Climb
www.nasdaq.com - July 14 at 3:32 PM |
 | Top Analyst Upgrades and Downgrades: Alphabet, Boeing, CyberArk, Eiger BioPharma, Hewlett Packard Enterprise, Snap, Ulta Beauty, Walmart and More
247wallst.com - July 14 at 3:32 PM |
| Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 14 at 12:33 PM |
| Eiger BioPharmaceuticals (EIGR) Sells Non-Strategic Assets to ... - StreetInsider.com
www.streetinsider.com - June 30 at 6:29 PM |
| Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
finance.yahoo.com - June 29 at 7:44 PM |
| -$1.27 EPS Expected for Eiger BioPharmaceuticals, Inc. (EIGR) This Quarter
www.americanbankingnews.com - June 26 at 4:08 PM |
| Eiger BioPharmaceuticals' (EIGR) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - June 25 at 7:26 PM |
| Eiger BioPharmaceuticals, Inc. Forecasted to Post Q2 2017 Earnings of ($1.19) Per Share (EIGR)
www.americanbankingnews.com - June 23 at 8:02 AM |
| Does Eiger BioPharmaceuticals Really Have 400% Upside? - 24/7 Wall St.
247wallst.com - June 21 at 6:28 PM |
| Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
finance.yahoo.com - June 14 at 6:01 PM |
| Eiger BioPharmaceuticals (EIGR) Presents Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9 ... - StreetInsider.com
www.streetinsider.com - June 14 at 5:32 AM |
| Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
finance.yahoo.com - June 12 at 5:50 PM |
| Eiger BioPharmaceuticals, Inc. (EIGR) to Post Q2 2017 Earnings of ($1.51) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - June 12 at 7:24 AM |
| Oppenheimer Holdings Inc. Analysts Give Eiger Biopharmaceuticals Inc (EIGR) a $34.00 Price Target
www.americanbankingnews.com - June 11 at 7:52 AM |
| Eiger BioPharmaceuticals (EIGR) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 5:57 PM |
| Eiger BioPharmaceuticals (EIGR) Reports Complete Enrollment for Phase 2 Multiple-Ascending Dose Study of Exendin ... - StreetInsider.com
www.streetinsider.com - June 8 at 2:33 AM |
| Eiger Biopharmaceuticals Inc (EIGR) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - June 6 at 6:55 PM |
| Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
finance.yahoo.com - June 6 at 5:19 PM |
| Zacks Investment Research Lowers Eiger Biopharmaceuticals Inc (EIGR) to Hold
www.americanbankingnews.com - June 5 at 7:32 PM |
| Eiger Biopharmaceuticals Inc (EIGR) Expected to Post Earnings of -$1.30 Per Share
www.americanbankingnews.com - May 31 at 12:46 PM |
| Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
finance.yahoo.com - May 30 at 11:32 AM |
| Eiger Biopharmaceuticals Inc (EIGR) Short Interest Up 8.7% in May
www.americanbankingnews.com - May 27 at 8:58 AM |
| Eiger Biopharmaceuticals Inc (EIGR) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 26 at 5:58 PM |
| Eiger BioPharmaceuticals (EIGR) Announces Results ... - StreetInsider.com
www.streetinsider.com - May 17 at 4:56 PM |
| Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
finance.yahoo.com - May 17 at 11:00 AM |
| Jefferies Group Equities Analysts Increase Earnings Estimates for Eiger Biopharmaceuticals Inc (EIGR)
www.americanbankingnews.com - May 17 at 8:00 AM |
| Eiger BioPharmaceuticals (EIGR) Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in PAH - StreetInsider.com
www.streetinsider.com - May 16 at 4:55 PM |
| Eiger Biopharmaceuticals' (EIGR) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 15 at 12:42 PM |
| Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
finance.yahoo.com - May 15 at 11:44 AM |
| Eiger Biopharmaceuticals Inc (EIGR) Issues Earnings Results
www.americanbankingnews.com - May 15 at 11:02 AM |
Eiger BioPharmaceuticals (EIGR) Chart for Monday, August, 21, 2017
